← FDA DRUG APPROVALS

FDA ANDA · ANDA074521

DIPYRIDAMOLE

Sponsor: HIKMA

APPLICATION
ANDA074521
TYPE
ANDA
ORIGINAL APPROVAL
1996-10-18
LATEST ACTION
2026-06-04
ROUTE
INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

DIPYRIDAMOLEPrescription
DIPYRIDAMOLE 5MG/ML · INJECTABLE · INJECTION

Approval history

2026-06-04Manufacturing (CMC) · Supplement 25 · standardAP
2001-01-11Manufacturing (CMC) · Supplement 8AP
1998-04-15Manufacturing (CMC) · Supplement 6AP
1997-09-05Labeling · Supplement 4AP
1997-09-05Manufacturing (CMC) · Supplement 5AP
1997-09-05Manufacturing (CMC) · Supplement 3AP
1997-04-29Manufacturing (CMC) · Supplement 2AP
1997-04-29Manufacturing (CMC) · Supplement 1AP
1996-10-18OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →